Date: 2013-06-17
Type of information: Grant
Company: Athera Biotechnologies (Sweden)
Investors: European Commission’s Seventh Framework Program (FP7)
Amount: € 6 million
Funding type: grant
Planned used: The grant will be used to fund future development costs of the fully human antibody PC-mAb up until proof-of-concept.
Others: * On June 17, 2013, Athera Biotechnologies has announced that future development costs of its fully human antibody PC-mAb up until proof-of-concept will be co-funded by the European Union’s Seventh Framework Programme for Research (FP7) through a collaborative research grant. Karolinska Development AB owns 65% of Athera Biotechnologies AB. Athera’s fully human monoclonal antibody PC-mAb is targeting phosphorylcholine and is being developed for the treatment of patients with an increased risk of atherosclerosis related cardiovascular events and death. This includes myocardial infarction patients and patients with peripheral arterial disease undergoing vein graft surgery.
The EUR 6m grant has been provided to the CARDIMMUN consortium, consisting of Athera, Leiden University Medical Center (LUMC), Turku PET Center (Turku University), Clinical Trial Consultants (CTC) and Smerud Medical Research. The project has a total budget of nearly € 8 million, and will be running over three years, focusing on key preclinical activities and clinical trials aimed at demonstrating proof-of-concept of this new cardiovascular treatment. LUMC is the project coordinator and will be leading the project together with Athera.
Therapeutic area: Cardiovascular diseases
